Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ginkgo Bioworks reports strong Q4 earnings, eyes biopharma growth

Ginkgo Bioworks reports strong financial performance and strategic growth in Q4 2022, focusing on downstream value share and biosecurity leadership.
While facing challenges with negative EBITDA, the company aims to drive efficiency, expand biosecurity initiatives, and capitalize on opportunities in biopharma and API manufacturing.
With a solid financial foundation, Ginkgo is well-positioned to leverage its expertise in programming cells and proprietary protein sequences for future growth and market expansion.

Ginkgo Bioworks reports strong Q1 growth and eyes global expansion

Ginkgo Bioworks showcased strong performance in Cell Engineering and Biosecurity revenue, emphasizing platform improvement and strategic partnerships.
While facing challenges in enterprise sales and operating expenses, the company is well-positioned for growth through international biosecurity expansion and biopharma focus.
Opportunities lie in global biosecurity initiatives, biopharma sales pipeline, and persistent monitoring programs, signaling a promising future for Ginkgo.

Ginkgo Bioworks posts robust Q2 results, eyes revenue diversification

Ginkgo Bioworks reported strong growth in revenue and active programs, with a focus on operational efficiencies and customer relationships.
Transitioning to success-based pricing models and task-specific data training positions the company for revenue diversification and enhanced customer value.
While facing market challenges and funding constraints, Ginkgo is strategically expanding its offerings and driving towards profitability through operational enhancements.

Ginkgo Bioworks reports strong Q3 performance and biosecurity opportunities

Ginkgo Bioworks reports strong performance with revenue growth and increased active programs.
The company's strengths lie in AI progress, diverse customer base, and biosecurity applications.
Challenges include deal timing, competitive positioning, and managing operational expenses.
Opportunities include tech licensing deals, AI-driven efficiency, and synergies between biosecurity and cell engineering.

Ginkgo Bioworks navigates revenue challenges with strategic growth initiatives

Ginkgo Bioworks faces revenue challenges from program dynamics but is strategically positioned for growth through R&D investments and partnerships.
The company's focus on innovation, efficiency, and biosecurity infrastructure underscores its commitment to leading in biotech R&D.
Opportunities in expanding partnerships, enhancing automation technology, and standardizing interfaces signal a promising path for Ginkgo's future growth.
Despite short-term revenue setbacks, Ginkgo's strategic initiatives and industry positioning bode well for long-term success and market leadership.

Ginkgo Bioworks targets EBITDA breakeven by 2026 amid revenue challenges

Ginkgo Bioworks is navigating challenges in revenue growth while focusing on cost reductions and operational efficiency to achieve EBITDA breakeven by 2026.
The company's strategic shift towards biopharma and bioAg sectors showcases flexibility and growth potential in serving large companies with research budgets.
Introduction of 'Lab Data as a Service' and focus on streamlining workflows present opportunities for scalability and revenue enhancement.
Despite challenges in revenue outlook and restructuring efforts, Ginkgo remains committed to operational success and financial sustainability.

Ginkgo Bioworks advances cost-saving goals amidst revenue challenges

Ginkgo Bioworks progresses towards financial targets amidst revenue challenges and aggressive cost-saving measures.
Strategic focus on automation, biosecurity, and revenue diversification positions the company for future growth.
Challenges include revenue decline, employee impact from layoffs, and balancing cost reduction with innovation.
Opportunities lie in new revenue streams, margin accretive initiatives, and market differentiation through mission-driven approach.

Ginkgo Bioworks reports mixed Q3 results, focuses on growth strategies

Ginkgo Bioworks showed strength in cost-cutting, revenue generation, and strategic focus, despite a negative adjusted EBITDA.
Challenges include financial pressures, margin concerns, and potential risks in resource utilization and funding stability.
Opportunities lie in new offerings, AI capabilities, market expansion, and revenue scale for improved profitability.
Management's emphasis on cost reduction, revenue growth, and innovation positions the company for long-term success and sustainability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Scorpion Capital is shooting some venom at a new target today.

Here's Why This Cathie Wood Stock Is Crashing Today

The decline in Ginkgo hurts investors like Ark Invest, which owned a combined $325 million stake in two of its ETFs.

Ginkgo Bioworks plunges 24% after short-seller calls it a 'Frankenstein mash-up of the worst frauds'

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) resulting from allegations that Ginkgo may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Ginkgo securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang

DNA INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Ginkgo Bioworks Holdings, Inc. Investors with Losses to Inquire About Class Action Investigation – DNA

And it has a really great ticker that many other biotechs might envy.

Here's an Up-and-Coming Biotech Stock to Watch With a Cannabis Connection

Seeing a potential value opportunity in a newly public company, Viking Global leader Andreas Halvorsen (Trades, Portfolio) disclosed a stake in Ginkgo Bioworks Holdings Inc. ( DNA , Financial) earlier this week.

Andreas Halvorsen Discloses Stake in Ginkgo Bioworks Following Market Debut

While the market for IPOs is always risky and unpredictable, it's an enticing sector that can potentially facilitate massive gains. The post 7 Companies Set to IPO That Could Be the Next Big Thing appeared first on InvestorPlace.

7 Companies Set to IPO That Could Be the Next Big Thing

Abbott Labs

American Well Corporation

CVS Health

Pfizer

Talkspace

Welltower

Thanks to the coronavirus pandemic, many people are rethinking the medical sector, boding well for healthcare stocks. The post 7 Healthcare Stocks to Buy Now as the Pandemic Forces a Rethink appeared first on InvestorPlace.

7 Healthcare Stocks to Buy Now as the Pandemic Forces a Rethink

A new analyst rating has investors excited.

Why Shares of Ginkgo Bioworks Are Rising Today

Some 400 Ginkgo Bioworks employees traveled to NYC to celebrate the company's first day of trading on the NYSE. Many were now millionaires, while Ginkgo's five founders' stakes approached $1 billion each at day's end.

As Synthetic Biology Company Ginkgo Bioworks Starts Trading, Its Five Founders Briefly Become Billionaires

Helbiz

Target

Walmart

A Christmas toy shortage for 2021 seems likely as retailers struggle to get enough inventory for the upcoming holiday shopping season. The post Toy Shortage Christmas 2021: 11 Things Consumers and Investors Can Expect appeared first on InvestorPlace.

Toy Shortage Christmas 2021: 11 Things Consumers and Investors Can Expect

Ginkgo Bioworks knows about growth and so far, it seems as though DNA stock does as well as it kicks off under an aptly titled ticker. The post DNA Stock Cooks Up 10% Gains on Ginkgo Biowork's First Trading Day appeared first on InvestorPlace.

DNA Stock Cooks Up 10% Gains on Ginkgo Biowork's First Trading Day

Ginkgo Bioworks (DNA) stock is set to start trading today as the company completes its merger with SPAC Soaring Eagle (SRNG). The post SRNG, DNA: 14 Things to Know About Ginkgo Bioworks and the Soaring Eagle SPAC Merger appeared first on InvestorPlace.

SRNG, DNA: 14 Things to Know About Ginkgo Bioworks and the Soaring Eagle SPAC Merger

Boston-based Ginkgo Bioworks began trading on the New York Stock Exchange on Friday, becoming the latest company to close a SPAC merger and go public.

Ginkgo Bioworks begins trading on the NYSE after completing SPAC merger

Soaring Eagle Acquisition Corp

BOSTON, Sept. 17, 2021 /PRNewswire/ -- Ginkgo Bioworks, Inc. ("Ginkgo") and Soaring Eagle Acquisition Corp. (Nasdaq: SRNG) ("Soaring Eagle"), a special purpose acquisition company, today announced the closing of their previously announced business combination.

Ginkgo Bioworks to Begin Trading Today as NYSE: DNA with Over $1.6 Billion in Proceeds

News for Ginkgo Bioworks Holdings Stock (DNA)